Newsroom | 49444 results

DUBLIN--(BUSINESS WIRE)--The "Auditing and Qualifying Suppliers and Vendors: An Effective Risk-based Approach (Mar 3rd - Mar 5th, 2026)" training has been added to ResearchAndMarkets.com's offering. Supplier or vendor qualification is a crucial component in compliance to 21 CFR 111. The FDA requires that manufacturers of dietary supplements, Pharmaceuticals, Biotech and Medical Device must "qualify" each of their vendors but do not provide guidance on how a company is to perform this qualificat...

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Miach Orthopaedics' BEAR Implant label updated to include significantly lower risk of post-traumatic osteoarthritis following ACL injury....

URBANA–CHAMPAIGN, Ill.--(BUSINESS WIRE)--Dr. Adil Haider, a globally recognized surgeon-scientist, academic leader, and founder of Boston Health AI, has been appointed as the Inaugural Chief Artificial Intelligence Officer (CAIO) at The Carle Illinois College of Medicine (CI-MED), the world’s first engineering-based medical school. Dr. Haider will lead the strategic vision and responsible deployment of artificial intelligence across the College of Medicine, advancing AI-enabled medical educatio...

IRVINE, Calif.--(BUSINESS WIRE)--Immunis, a clinical-stage biotech company pioneering multi-active secretome-based biologics, today announced positive topline interim results from STEM-META, a double-blind placebo-controlled study of the IMM01-STEM secretome in overweight seniors experiencing muscle loss and metabolic dysfunction. In recognition of the news, Immunis Chairman, Dr. Hans Keirstead, will be speaking at Biotech Showcase on a panel about cutting-edge immune-based therapeutics. The st...

MORRISVILLE, N.C.--(BUSINESS WIRE)--WEP Clinical (WEP), a full-service contract research organization (CRO), announces the acquisition of Siron Clinical (Siron), a Netherlands-based European CRO specializing in flexible, high-quality clinical operations for biotech companies. The acquisition expands WEP’s global footprint and strengthens its ability to deliver end-to-end Phase I–IV clinical trial solutions across complex, rare, and specialized therapeutic areas. Founded in 2000, Siron is headqu...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caldera Therapeutics, Inc. (Caldera), a clinical stage biotechnology company developing the first-in-class bispecific antibody CLD-423 for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, today launched with $112.5 million total capital raised and announced that the first subjects have been dosed in the Phase 1 trial of its lead program, CLD-423. Caldera raised a $75 million Series A round from Atlas Venture, LAV and venBio, an...

PARIS--(BUSINESS WIRE)--Genethon's agreement with AskBio, enables the development of a gene therapy for patients suffering from this particularly severe condition...

SAN FRANCISCO--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, is participating in the 44th J.P. Morgan Healthcare Conference 2026, taking place from 12th to 14th January 2026 in San Francisco, to provide an update on its business strategy, pipeline advancement, and business outlook. The company’s CEO and president, Carlos Gallardo, presents an update on the progress of the R&D pipeline in medical dermatology which is focused on devel...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The company will share data from five abstracts on two neuromodulators from its portfolio, Relfydess – the first and only ready-to-use liquid neuromodulator designed with PEARL Technology – and Dysport. Additionally, Galderma will be hosting a Relfydess Masterclass in which...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.（NASDAQ：ONC、HKEX：06160、SSE：688235）は、サンフランシスコで開催される第44 回「JPモルガン・ヘルスケア・カンファレンス」におけるプレゼンテーションで、拡大を続ける同社のオンコロジー領域のグローバルなリーダーシップを支える柱を示します。 BeOneの共同創業者で取締役会会長兼最高経営責任者（CEO）であるジョン・V・オイラーは、B細胞性悪性腫瘍の治療における同社の変革的なリーダーシップを強調します。本プレゼンテーションでは、ブルトン型チロシンキナーゼ（BTK）阻害薬の中で世界的に最も有力なBRUKINSA®に加え、血液がん領域の基盤となる資産として、次世代でベストインクラスとなる可能性を有するB細胞リンパ腫2（BCL2）阻害薬ソンロトクラックス（12月30日に初のグローバル規制当局承認を取得済）およびファーストインクラスかつベストインクラスとなる可能性を有するBTKを標的とするキメラ分解活...